WuXi PharmaTech Begins Construction On Manufacturing Facility In Philadelphia, Pennsylvania
The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility.
Located in the Philadelphia Navy Yard, company officials said its new facility will complement WuXi's existing facility and capabilities which include analytical chemistry, cell banking, cell characterization, molecular biology and lot release testing, thereby providing fully integrated services for cell therapies in Philadelphia.
"Cell therapies offer important treatment options, and WuXi is committed to bringing them to patients faster," said Dr. Ge Li, Chairman/CEO of PharmaTech.
The company said “this expansion will support growing customer demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics. The new facility will be built using advanced modular design, with flexible clean room technology, disposable equipment, and microcarrier cell culture systems.”
Beam Therapeutics Selects Research Triangle Park, North Carolina, for Research and Production Campus
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
How are Uncertain Times Altering Company Location Strategies?
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
A Heightened Focus on Reshoring
34th Annual Corporate Survey & the 16th Annual Consultants Survey